The FSSAI has issued notices to Nestle India and Hindustan Unilever regarding inconsistent product labeling and unsubstantiated health claims. The regulator cited issues with popular items like Nescafé coffee drinks and Horlicks variants, challenging the marketing narratives of these FMCG giants. Investors should monitor how the companies address these compliance demands and whether they need to modify their advertising or packaging strategies.
The Food Safety and Standards Authority of India (FSSAI) has initiated a regulatory crackdown targeting two of India’s largest fast-moving consumer goods (FMCG) companies, Nestle India and Hindustan Unilever (HUL). The regulator has issued formal notices citing concerns over inconsistent product labeling and claims that may not align with established safety and nutritional standards.
Scrutiny on Product Labeling and Claims
Nestle India has been flagged for discrepancies regarding its Nescafé chilled coffee range. The regulator noted inconsistencies between the product’s back-of-pack declarations and its online listings. While the product was sold as "Flavoured Milk" on certain platforms, it was categorized as "Proprietary Food" on packaging. The FSSAI also raised concerns about marketing claims like "crafted with the goodness of flavoured double toned milk," suggesting these descriptions did not match the actual composition of the product. Additionally, the regulator flagged Nestle’s "Renal Resource" vanilla powder, stating that the product, intended for medical dietary needs, was marketed without the mandatory prior approval required under food safety laws.
Meanwhile, Hindustan Unilever faces regulatory scrutiny over marketing claims associated with its Horlicks brand. The FSSAI contested health-related assertions on "Horlicks Women’s Plus" regarding bone strength, noting that the product failed to adhere to prescribed nutritional standards for calcium, vitamin D, and vitamin K2. Similarly, claims related to "Healthy Birth Weight" on "Horlicks Mother’s Plus Kesar" were deemed unsubstantiated. These actions appear to be part of the regulator's push to strictly enforce the Food Safety and Standards (Advertising and Claims) Regulations of 2018.
Investor Context and Regulatory Impact
For major FMCG companies, premium branding and health-focused marketing are central to maintaining market share and justifying price points. When regulators challenge these claims, companies often face the risk of being forced to rebrand, change packaging, or even reformulate products, which can lead to increased costs and temporary disruption in sales.
Beyond these corporate notices, the FSSAI is intensifying its oversight of the broader food supply chain. The regulator recently suspended the operating licenses of Sukhdarshan Pharma and Bala Ji Food Products due to severe hygiene and sanitation violations. This wider enforcement drive signals that the agency is tightening its grip on both major manufacturers and smaller players to ensure stricter adherence to safety protocols.
Investors should track the companies' official responses and any subsequent changes to product labeling or marketing materials. The primary monitorable is whether these notices lead to mandatory product recalls or significant revisions to the advertising strategies that have historically supported these products. Any prolonged regulatory back-and-forth could affect brand trust and compliance costs, which are key metrics for long-term health in the consumer goods sector.